FDA Approves First Muscle-Targeted Therapy for SMA

Innovations in Care

We provide programs and services that transform the lives of people affected by neuromuscular disease.

Servier & Muscular Dystrophy: Partnering for Progress in Rare Diseases

October 8th, 2026
12:00 PM ET
Live, Virtual Webinar

Join us to get to know Servier Pharmaceuticals and learn more about its growing commitment to the muscular dystrophy community. Following Servier’s acquisition of Edgewise Therapeutics’ muscular dystrophy programs, this webinar will introduce Servier, share more about its focus on addressing unmet needs in rare diseases and look ahead to how Servier plans to listen, learn and work alongside patients, families and advocates in the Becker community.

Register


Thank you to our supporter:

Servier logo